Phase 2CompletedINTERVENTIONAL
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
ClinicalTrials.gov · NCT05877547 · Registry updated: 2026-01-12
- Condition / research focus
- Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis
- Sponsor
- Merck Sharp & Dohme LLC
- Countries with listed sites
- Austria · Belgium · Canada · Chile · China · Colombia · Czechia · France · Hong Kong · Hungary · Israel · Italy · Japan · Mexico · Peru · Portugal · Puerto Rico · Singapore · South Korea · Spain · Switzerland · Taiwan · Thailand · Turkey (Türkiye) · United Kingdom · United States
- Registry dates and results
- Start: 2023-06-23. Completion: 2025-12-29 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Efinopegdutide (drug) — also listed as: MK-6024, HM12525A, JNJ-64565111
- Semaglutide (drug) — also listed as: Wegovy
- Placebo (drug)
Where the study takes place — 175 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.